[New post] CIMB: Duopharma Biotech Bhd

alanyeo posted: " 1HFY21: Steady demand despite challenges■ 1HFY21 core net profit growth was 3.1% yoy, in line with expectations. Salesgrowth was driven by the public sector and consumer healthcare segment.■ We expect meaningful contribution to arise from the supply of t" Respond to this post by replying above this line New post on Alpha Edge Investing CIMB: Duopharma Biotech Bhd by alanyeo 1HFY21: Steady demand despite challenges■ 1HFY21 core net profit growth was 3.1% yoy, in line with expectations. Salesgrowth was driven by the public sector and consumer healthcare segment.■ We expect meaningful contribution to arise from the supply of the SinopharmCovid-19 vaccine to the private sector in 2HFY21F.■ Reiterate Add with a lower TP of RM3.16 […] Read more of this post alanyeo | August 19, 2021 at 1:18 pm | Tags: Duopharma Biotech Bhd | Categories: Equities - Research Reports by Brokers/ Banks | URL: https://wp.me/p7fA1-35x Comment    See all comments    Like Unsubscribe to no longer receive posts from Alpha Edge Investing. Change your email settings at Manage Subscriptions. Trouble clicking? Copy and paste this URL into your browser: http://alphaedgeinvesting.com/2021/08/19/cimb-duopharma-biotech-bhd-2/ Thanks for flying with WordPress.com